Related Experiment Video
Updated: Jun 21, 2026
Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye
Published on: November 25, 2012
Late gene therapy limits the restoration of retinal function in a mouse model of retinitis pigmentosa
Miranda L Scalabrino1,2, Mishek Thapa1,2, Tian Wang3
1Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA, USA.
Abstract:
Retinitis pigmentosa is an inherited photoreceptor degeneration that begins with rod loss followed by cone loss. This cell loss greatly diminishes vision, with most patients becoming legally blind. Gene therapies are being developed, but it is unknown how retinal function depends on the time of intervention. To uncover this dependence, we utilize a mouse model of retinitis pigmentosa capable of artificial genetic rescue. This model enables a benchmark of best-case gene therapy by removing variables that complicate answering this question. Complete genetic rescue was performed at 25%, 50%, and 70% rod loss (early, mid and late, respectively). Early and mid treatment restore retinal output to near wild-type levels. Late treatment retinas exhibit continued, albeit slowed, loss of sensitivity and signal fidelity among retinal ganglion cells, as well as persistent gliosis. We conclude that gene replacement therapies delivered after 50% rod loss are unlikely to restore visual function to normal. This is critical information for administering gene therapies to rescue vision.
Insights
Gene therapy for retinitis pigmentosa (RP) is most effective when initiated early. Intervening after 50% rod loss significantly impairs vision restoration, highlighting the critical timing for RP gene therapies.
Area of Science:
- Ophthalmology
- Genetics
- Neuroscience
Background:
- Retinitis pigmentosa (RP) is an inherited retinal degeneration causing progressive vision loss.
- Current gene therapies for RP aim to restore photoreceptor function but optimal intervention timing remains unclear.
Purpose of the Study:
- To determine the impact of intervention timing on the efficacy of gene therapy for retinitis pigmentosa.
- To establish a benchmark for best-case gene therapy outcomes by controlling for confounding variables.
Main Methods:
- Utilized a mouse model of retinitis pigmentosa with artificial genetic rescue capabilities.
- Administered complete genetic rescue at different stages of rod loss: 25% (early), 50% (mid), and 70% (late).
- Assessed retinal function and cell integrity following gene therapy intervention.
Main Results:
- Early (25%) and mid (50%) stage genetic rescue restored retinal output to near wild-type levels.
- Late stage (70%) rescue resulted in continued, though slowed, loss of retinal ganglion cell sensitivity and signal fidelity.
- Persistent gliosis was observed in retinas treated at the late stage.
Conclusions:
- Gene replacement therapy for retinitis pigmentosa is unlikely to restore normal visual function if initiated after 50% rod loss.
- These findings underscore the critical importance of early intervention timing for successful gene therapy in RP patients.
- The study provides crucial data for optimizing the clinical application of gene therapies aimed at vision rescue.
